REPORT ID 6552

EMEA (Europe, Middle East and Africa) Intravenous-to-Subcutaneous Drug Market Report 2017

Publish Date
26-Dec-17
Pages
104
Format
Electronic (PDF)

In this report, the EMEA Intravenous-to-Subcutaneous Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Intravenous-to-Subcutaneous Drug for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Intravenous-to-Subcutaneous Drug market competition by top manufacturers/players, with Intravenous-to-Subcutaneous Drug sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Novartis
    GSK
    Merck
    ...

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Prescription
    OCT

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Medical Center

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Intravenous-to-Subcutaneous Drug Market Report 2017
1 Intravenous-to-Subcutaneous Drug Overview
    1.1 Product Overview and Scope of Intravenous-to-Subcutaneous Drug
    1.2 Classification of Intravenous-to-Subcutaneous Drug
        1.2.1 EMEA Intravenous-to-Subcutaneous Drug Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Intravenous-to-Subcutaneous Drug Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Prescription
        1.2.4 OCT
    1.3 EMEA Intravenous-to-Subcutaneous Drug Market by Application/End Users
        1.3.1 EMEA Intravenous-to-Subcutaneous Drug Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospital
        1.3.3 Medical Center
    1.4 EMEA Intravenous-to-Subcutaneous Drug Market by Region
        1.4.1 EMEA Intravenous-to-Subcutaneous Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Intravenous-to-Subcutaneous Drug (2012-2022)
        1.5.1 EMEA Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Intravenous-to-Subcutaneous Drug Revenue and Growth Rate (2012-2022)

2 EMEA Intravenous-to-Subcutaneous Drug Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Intravenous-to-Subcutaneous Drug Market Competition by Players/Manufacturers
        2.1.1 EMEA Intravenous-to-Subcutaneous Drug Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Intravenous-to-Subcutaneous Drug Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Intravenous-to-Subcutaneous Drug Sale Price by Players (2012-2017)
    2.2 EMEA Intravenous-to-Subcutaneous Drug (Volume and Value) by Type/Product Category
        2.2.1 EMEA Intravenous-to-Subcutaneous Drug Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Intravenous-to-Subcutaneous Drug Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Intravenous-to-Subcutaneous Drug Sale Price by Type (2012-2017)
    2.3 EMEA Intravenous-to-Subcutaneous Drug (Volume) by Application
    2.4 EMEA Intravenous-to-Subcutaneous Drug (Volume and Value) by Region
        2.4.1 EMEA Intravenous-to-Subcutaneous Drug Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Intravenous-to-Subcutaneous Drug Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Intravenous-to-Subcutaneous Drug Sales Price by Region (2012-2017)

3 Europe Intravenous-to-Subcutaneous Drug (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Intravenous-to-Subcutaneous Drug Sales and Value (2012-2017)
        3.1.1 Europe Intravenous-to-Subcutaneous Drug Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Intravenous-to-Subcutaneous Drug Revenue and Growth Rate (2012-2017)
    3.2 Europe Intravenous-to-Subcutaneous Drug Sales and Market Share by Type
    3.3 Europe Intravenous-to-Subcutaneous Drug Sales and Market Share by Application
    3.4 Europe Intravenous-to-Subcutaneous Drug Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Intravenous-to-Subcutaneous Drug Sales Volume by Countries (2012-2017)
        3.4.2 Europe Intravenous-to-Subcutaneous Drug Revenue by Countries (2012-2017)
        3.4.3 Germany Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        3.4.4 France Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        3.4.5 UK Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        3.4.6 Russia Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        3.4.7 Italy Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)

4 Middle East Intravenous-to-Subcutaneous Drug (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Intravenous-to-Subcutaneous Drug Sales and Value (2012-2017)
        4.1.1 Middle East Intravenous-to-Subcutaneous Drug Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Intravenous-to-Subcutaneous Drug Revenue and Growth Rate (2012-2017)
    4.2 Middle East Intravenous-to-Subcutaneous Drug Sales and Market Share by Type
    4.3 Middle East Intravenous-to-Subcutaneous Drug Sales and Market Share by Application
    4.4 Middle East Intravenous-to-Subcutaneous Drug Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Intravenous-to-Subcutaneous Drug Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Intravenous-to-Subcutaneous Drug Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        4.4.4 Israel Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        4.4.5 UAE Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        4.4.6 Iran Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)

5 Africa Intravenous-to-Subcutaneous Drug (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Intravenous-to-Subcutaneous Drug Sales and Value (2012-2017)
        5.1.1 Africa Intravenous-to-Subcutaneous Drug Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Intravenous-to-Subcutaneous Drug Revenue and Growth Rate (2012-2017)
    5.2 Africa Intravenous-to-Subcutaneous Drug Sales and Market Share by Type
    5.3 Africa Intravenous-to-Subcutaneous Drug Sales and Market Share by Application
    5.4 Africa Intravenous-to-Subcutaneous Drug Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Intravenous-to-Subcutaneous Drug Sales Volume by Countries (2012-2017)
        5.4.2 Africa Intravenous-to-Subcutaneous Drug Revenue by Countries (2012-2017)
        5.4.3 South Africa Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Intravenous-to-Subcutaneous Drug Sales and Growth Rate (2012-2017)

6 EMEA Intravenous-to-Subcutaneous Drug Manufacturers/Players Profiles and Sales Data
    6.1 Novartis
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Intravenous-to-Subcutaneous Drug Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Novartis Intravenous-to-Subcutaneous Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 GSK
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Intravenous-to-Subcutaneous Drug Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 GSK Intravenous-to-Subcutaneous Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Merck
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Intravenous-to-Subcutaneous Drug Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Merck Intravenous-to-Subcutaneous Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    ...

7 Intravenous-to-Subcutaneous Drug Manufacturing Cost Analysis
    7.1 Intravenous-to-Subcutaneous Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Intravenous-to-Subcutaneous Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Intravenous-to-Subcutaneous Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Intravenous-to-Subcutaneous Drug Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Intravenous-to-Subcutaneous Drug Market Forecast (2017-2022)
    11.1 EMEA Intravenous-to-Subcutaneous Drug Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Intravenous-to-Subcutaneous Drug Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Intravenous-to-Subcutaneous Drug Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Intravenous-to-Subcutaneous Drug Price and Trend Forecast (2017-2022)
    11.2 EMEA Intravenous-to-Subcutaneous Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Intravenous-to-Subcutaneous Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Intravenous-to-Subcutaneous Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Intravenous-to-Subcutaneous Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Intravenous-to-Subcutaneous Drug Sales Forecast by Type (2017-2022)
    11.7 EMEA Intravenous-to-Subcutaneous Drug Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer